Literature DB >> 20686367

SU11248, a selective tyrosine kinases inhibitor suppresses breast tumor angiogenesis and growth via targeting both tumor vasculature and breast cancer cells.

Emily Young1, Lucio Miele, Kevan B Tucker, Min Huang, Jeremy Wells, Jian-Wei Gu.   

Abstract

SU11248 is a selective inhibitor of certain protein kinases including VEGFR types 1-3 that are expressed in human breast cancer. The present study determines whether the anti-tumor activity of SU11248 results from the inhibition of angiogenesis, as well as direct anti-proliferation and anti-migration effects on breast tumors. Eight-wk old female mice (C57BL/6) were given SU11248 at 20-40 mg/kg/d in drinking (distilled) water for 4 wks. Control mice received drinking water only. In the 2nd wk, 10(6) E0771 (mouse breast cancer) cells were injected in the left fourth mammary gland. Tumor size was monitored using dial calipers. At the end, tumors were isolated for measuring tumor size and intratumoral microvessel density (IMD) using CD31 immunohistochemistry. SU11248 significantly reduced tumor weight over the control (1.22 ± 0.28 vs. 3.28 ± 0.31 g; n = 8; p < 0.01) and IMD (111 ± 10 vs. 155 ± 6 IM#/mm2; p < 0.01). RT-PCR indicated that VEGFR1 and R2 were expressed in cultured E0771 cells. VEGF (10 ng/ml) caused a 42% increase in proliferation of E0771 cells, compared to the control (p < 0.01; n = 8), and there was a significant decrease in proliferation of E0771 cells treated with VEGF plus SU11248 (10 μmol/L) vs. the control (65%, p < 0.01). VEGF caused a 2-fold increase in the proliferation of HUVEC vs. the control (p < 0.01; n = 8), but its action was completely eradicated by SU11248. Neither VEGF nor SU11248 had any effect on the proliferation of cultured HAS MC. Migration assay showed that SU11248 (10 μmol/L) significantly inhibited the migration of cultured E0771 cells. SU11248 significantly inhibited the proliferation of MCF-7 and MDAMB-231 cells in a dose-related manner. These findings support the hypothesis that the antitumor activity of SU11248 on breast cancer is possibly mediated by targeting the paracrine and autocrine effects of VEGF on breast cancer to suppress tumor angiogenesis, proliferation and migration.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20686367      PMCID: PMC3230514          DOI: 10.4161/cbt.10.7.12904

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  31 in total

Review 1.  Nuclear factor-kappaB in cancer development and progression.

Authors:  Michael Karin
Journal:  Nature       Date:  2006-05-25       Impact factor: 49.962

2.  Angiogenesis and breast cancer.

Authors:  J Folkman
Journal:  J Clin Oncol       Date:  1994-03       Impact factor: 44.544

3.  Role of vascular endothelial growth factor in the stimulation of cellular invasion and signaling of breast cancer cells.

Authors:  D J Price; T Miralem; S Jiang; R Steinberg; H Avraham
Journal:  Cell Growth Differ       Date:  2001-03

4.  Enhanced intrinsic migration of aggressive breast cancer cells by inhibition of Rac1 GTPase.

Authors:  Yufeng Zuo; Sarah-Kim Shields; Chandan Chakraborty
Journal:  Biochem Biophys Res Commun       Date:  2006-10-16       Impact factor: 3.575

Review 5.  Tumor angiogenesis: therapeutic implications.

Authors:  J Folkman
Journal:  N Engl J Med       Date:  1971-11-18       Impact factor: 91.245

6.  Vascular endothelial growth factors are differentially regulated by steroid hormones and antiestrogens in breast cancer cells.

Authors:  J K Ruohola; E M Valve; M J Karkkainen; V Joukov; K Alitalo; P L Härkönen
Journal:  Mol Cell Endocrinol       Date:  1999-03-25       Impact factor: 4.102

7.  Molecular profiling of angiogenesis markers.

Authors:  Shu-Ching Shih; Gregory S Robinson; Carole A Perruzzi; Alfonso Calvo; Kartiki Desai; Jeffery E Green; Iqbal U Ali; Lois E H Smith; Donald R Senger
Journal:  Am J Pathol       Date:  2002-07       Impact factor: 4.307

8.  Markedly improved efficacy of edatrexate compared to methotrexate in a high-dose regimen with leucovorin rescue against metastatic murine solid tumors.

Authors:  F M Sirotnak; G M Otter; F A Schmid
Journal:  Cancer Res       Date:  1993-02-01       Impact factor: 12.701

Review 9.  Nuclear factor-kappa B and cancer: its role in prevention and therapy.

Authors:  Alok C Bharti; Bharat B Aggarwal
Journal:  Biochem Pharmacol       Date:  2002-09       Impact factor: 5.858

Review 10.  Targeting signal transduction pathways in metastatic breast cancer: a comprehensive review.

Authors:  Lee S Rosen; Helen Louise Ashurst; Linnea Chap
Journal:  Oncologist       Date:  2010-03-03
View more
  15 in total

1.  Deciphering the anticancer mechanisms of sunitinib.

Authors:  Sumanta Kumar Pal; Robert A Figlin; Hua Yu
Journal:  Cancer Biol Ther       Date:  2010-10-01       Impact factor: 4.742

2.  Increased plasma levels of soluble vascular endothelial growth factor receptor 1 (sFlt-1) in women by moderate exercise and increased plasma levels of vascular endothelial growth factor in overweight/obese women.

Authors:  Kristina L Makey; Sharla G Patterson; James Robinson; Mark Loftin; Dwight E Waddell; Lucio Miele; Edmund Chinchar; Min Huang; Andrew D Smith; Mark Weber; Jian-Wei Gu
Journal:  Eur J Cancer Prev       Date:  2013-01       Impact factor: 2.497

3.  Postmenopausal obesity promotes tumor angiogenesis and breast cancer progression in mice.

Authors:  Jian-Wei Gu; Emily Young; Sharla G Patterson; Kristina L Makey; Jeremy Wells; Min Huang; Kevan B Tucker; Lucio Miele
Journal:  Cancer Biol Ther       Date:  2011-05-15       Impact factor: 4.742

4.  Escape from breast tumor dormancy: The convergence of obesity and menopause.

Authors:  Roopali Roy; Jiang Yang; Takaya Shimura; Lauren Merritt; Justine Alluin; Emily Man; Cassandra Daisy; Rama Aldakhlallah; Deborah Dillon; Susan Pories; Lewis A Chodosh; Marsha A Moses
Journal:  Proc Natl Acad Sci U S A       Date:  2022-10-03       Impact factor: 12.779

5.  Tumor Vascular Remodeling Affects Molecular Dissemination to Lymph Node and Systemic Leukocytes.

Authors:  Meghan J O'Melia; Nathan A Rohner; Susan Napier Thomas
Journal:  Tissue Eng Part A       Date:  2022-06-21       Impact factor: 4.080

6.  Cardiotoxicity associated with targeted cancer therapies.

Authors:  Z I Chen; D I Ai
Journal:  Mol Clin Oncol       Date:  2016-03-03

7.  Notch signals in the endothelium and cancer "stem-like" cells: opportunities for cancer therapy.

Authors:  Jian-Wei Gu; Paola Rizzo; Antonio Pannuti; Todd Golde; Barbara Osborne; Lucio Miele
Journal:  Vasc Cell       Date:  2012-04-09

8.  Monitoring therapeutic efficacy of sunitinib using [(18)F]FDG and [(18)F]FMISO PET in an immunocompetent model of luminal B (HER2-positive)-type mammary carcinoma.

Authors:  Benoît Thézé; Nicholas Bernards; Audrey Beynel; Stephan Bouet; Bertrand Kuhnast; Irène Buvat; Bertrand Tavitian; Raphaël Boisgard
Journal:  BMC Cancer       Date:  2015-07-22       Impact factor: 4.430

9.  Impairing flow-mediated endothelial remodeling reduces extravasation of tumor cells.

Authors:  Gautier Follain; Naël Osmani; Valentin Gensbittel; Nandini Asokan; Annabel Larnicol; Luc Mercier; Maria Jesus Garcia-Leon; Ignacio Busnelli; Angelique Pichot; Nicodème Paul; Raphaël Carapito; Seiamak Bahram; Olivier Lefebvre; Jacky G Goetz
Journal:  Sci Rep       Date:  2021-06-23       Impact factor: 4.379

10.  EGCG, a major green tea catechin suppresses breast tumor angiogenesis and growth via inhibiting the activation of HIF-1α and NFκB, and VEGF expression.

Authors:  Jian-Wei Gu; Kristina L Makey; Kevan B Tucker; Edmund Chinchar; Xiaowen Mao; Ivy Pei; Emily Y Thomas; Lucio Miele
Journal:  Vasc Cell       Date:  2013-05-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.